면책 고지: 이 사이트는 FDA, ClinicalTrials.gov, PubMed, SEC EDGAR 등 공식 공개 데이터를 일반 참고용으로 집계하며, 의학적 조언, 진단, 치료 권고 또는 투자 조언이 아닙니다.

임상시험

Oral Colloidal Silicon Dioxide Added to Routine Treatment for Acute Urticaria in the Emergency Department

NCT: NCT07866092 · COMPLETED

NCT IDNCT07866092
상태COMPLETED
시작일2026-08-24
완료2026-10-01
SponsorAnkara Etlik City Hospital (OTHER_GOV)
First posted
Last updated

간략 요약

The goal of this observational study is to learn whether adding a single oral dose of colloidal silicon dioxide, an enterosorbent, to routine emergency department treatment is associated with faster early improvement in adults with acute urticaria. The main question it aims to answer is: Is the change in urticaria activity over the first 2 hours different in patients who receive colloidal silicon dioxide in addition to intravenous pheniramine compared with patients who receive intravenous pheniramine alone? Treatment is chosen by the treating emergency physician as part of routine care, before patients are approached for the study. Participants are assessed before treatment and at 1 and 2 hours, and are contacted by telephone at 24 hours.

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.

↑